Healthcare
Kymera Therapeutics, Inc.(KYMR)
Live Price
Offline$98.12
+8.50% today
1Y Change
+97.83%
Window
Jun 26, 2025 โ Jun 18, 2026
- Market Cap
- $6.60B
- Revenue Growth
- -16.7%
- EPS Growth
- -23.8%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 26, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Kymera Therapeutics, Inc. (KYMR) is a Healthcare stock with a market cap of $6.60B and listed on NASDAQ. The stock last traded around $98.12 and up 97.8% across the available one-year price window (Jun 26, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -16.7%, EPS growth of -23.8%, a dividend yield of 0.0%. What stands out right now is revenue -16.7%, EPS -23.8%, free cash flow -13.0% with operating margin -697.8% and ROIC -22.2%. Valuation already assumes a fairly strong business story at price/sales 128.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines KYMR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-16.7% vs +7.6% peer median
Operating Margin
Below sector median
-697.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 8, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -16.7% and EPS is at -23.8%, with operating margin around -697.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -3.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 8, 2026 | โ | -2.3% | -4.5% | -14.1% |
2026 Feb 26, 2026 | -23.8% | -3.9% | -12.1% | -15.6% |
2025 Nov 4, 2025 | -26.8% | -0.0% | +5.8% | +10.1% |
Benchmark Edge
KYMR vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
KYMR
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
KYMR Max Drawdown
-27.74%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for KYMR and SPY.
Company Overview
Kymera Therapeutics, Inc.
NASDAQ Global Market
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
- Leadership
- Nello Mainolfi
- IPO Date
- Aug 21, 2020
- Employees
- 208
- Street Address
- 200 Arsenal Yards Boulevard
- Mailing
- Watertown, MA, 02472
- Region
- Watertown, MA, US
- Reporting Currency
- USD
- Investor Line
- 857 285 5300
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 128.3
- Price/Book
- 5.1
Growth
- Revenue
- -16.7%
- EPS
- -23.8%
- Free Cash Flow
- -13.0%
Profitability
- Gross Margin
- 33.2%
- Operating Margin
- -697.8%
- Net Margin
- -612.2%
- ROE
- -25.0%
- ROIC
- -22.2%
Balance Sheet
- Debt/Equity
- 0.05
- Current Ratio
- 10.81
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.